Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sepracor-Looks very promising -- Ignore unavailable to you. Want to Upgrade?

To: M. Ramle who wrote (2315)	4/15/1999 10:43:00 AM
From: Biomaven	Read Replies (2) \| Respond to of 10280

OK - I'm viewing this as one of SEPR's unexplained drops. I added to my position with some LEAPS when the stock was in the 97 range. You have to remember we ran up with essentially no new news - it was more a case of a bigger audience rather than real news. There could of course be some lurking bad news that we don't know about - e.g., the Allegra interference might be turning out adversely, or ditto for the FTC investigation, although I think that is very unlikely. The Xopenex label wasn't quite as good as I had hoped, and that might be part of the reason for the weakness. More likely, the increased near-term spending and the delay in the Xopenex roll-out is causing jitters in someone's earnings model. The weakness today in the big drug stocks isn't helping either. Peter